Elicio Therapeutics Company Insiders
| ELTX Stock | 4.93 0.19 3.71% |
Elicio Therapeutics employs about 32 people. The company is managed by 9 executives with a total tenure of roughly 75 years, averaging almost 8.0 years of service per executive, having 3.56 employees per reported executive. Break down of Elicio Therapeutics' management performance can provide insight into the company performance.
Elicio |
Elicio Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.968) % which means that it has lost $0.968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.5302) %, meaning that it created substantial loss on money invested by shareholders. Elicio Therapeutics' management efficiency ratios could be used to measure how well Elicio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.36 in 2024. Return On Capital Employed is likely to rise to -1.95 in 2024. At this time, Elicio Therapeutics' Other Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 30.05 in 2024, whereas Total Assets are likely to drop slightly above 20.5 M in 2024.Common Stock Shares Outstanding is likely to drop to about 4.4 M in 2024. Net Loss is likely to drop to about (26.7 M) in 2024
Elicio Therapeutics Workforce Comparison
Elicio Therapeutics is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 268,076. Elicio Therapeutics adds roughly 32.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Elicio Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elicio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elicio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Elicio Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haqq Christopher over a month ago Acquisition by Haqq Christopher of 28200 shares of Elicio Therapeutics at 5.03 subject to Rule 16b-3 | ||
Chudnovsky Yekaterina over six months ago Acquisition by Chudnovsky Yekaterina of 1032702 shares of Elicio Therapeutics at 0.01 subject to Rule 16b-3 | ||
Omenn Gilbert S over six months ago Conversion by Omenn Gilbert S of 23391 shares of Elicio Therapeutics | ||
Nissenson Allen over six months ago Acquisition by Nissenson Allen of 4100 shares of Elicio Therapeutics subject to Rule 16b-3 | ||
Nissenson Allen over six months ago Purchase by Nissenson Allen of 2037 shares of Elicio Therapeutics | ||
Neylan John F over a year ago Sale by Neylan John F of 442 shares of Elicio Therapeutics | ||
Rhodes Jennifer J over a year ago ELICIO THERAPEUTICS exotic insider transaction detected | ||
Ruffolo Robert R over a year ago ELICIO THERAPEUTICS exotic insider transaction detected |
Elicio Therapeutics Notable Stakeholders
An Elicio Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Elicio Therapeutics often face trade-offs trying to please all of them. Elicio Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Elicio Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Prof Irvine | Consultant, CoFounder | Profile | |
| Robert Connelly | President, CEO | Profile | |
| Joy Seymour | VP Affairs | Profile | |
| Esther Welkowsky | Senior Development | Profile | |
| Peter DeMuth | Chief Officer | Profile | |
| Michael DiVecchia | Senior Resources | Profile | |
| Megan Filoon | Secretary Counsel | Profile | |
| Brian Piekos | Chief Officer | Profile | |
| Thian Kheoh | Senior Biometrics | Profile |
About Elicio Therapeutics Management Performance
The success or failure of an entity such as Elicio Therapeutics often depends on how effective the management is. Elicio Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Elicio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Elicio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.30) | (1.36) | |
| Return On Capital Employed | (2.06) | (1.95) | |
| Return On Assets | (1.30) | (1.36) | |
| Return On Equity | (3.09) | (2.94) |
Please note, the imprecision that can be found in Elicio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elicio Therapeutics. Check Elicio Therapeutics' Beneish M Score to see the likelihood of Elicio Therapeutics' management manipulating its earnings.
Elicio Therapeutics Workforce Analysis
Traditionally, organizations such as Elicio Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Elicio Therapeutics within its industry.Elicio Therapeutics Manpower Efficiency
Return on Elicio Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 3.9M | |
| Working Capital Per Employee | 205.7K | |
| Working Capital Per Executive | 731.3K |
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.